Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 17, 2022
Data Byte
CHMP recommends approval of CSL’s gene therapy for hemophilia B
December highlights include AstraZeneca’s two CTLA-4 programs, negative opinion on Y-mAbs’ CD276 mAb
BioCentury | Nov 11, 2022
Discovery & Translation
S&K’s small molecule TNF inhibitor; plus Actym’s engineered bacteria platform and more
BioCentury’s roundup of translational news
BioCentury | Jun 25, 2022
Discovery & Translation
Expanding the CAR T cell toolbox
Snapshots from the literature add to the growing picture of next-gen CAR T manipulations that could enhance multiple cancer therapies
BioCentury | Jan 15, 2022
Discovery & Translation
HLA-independent TCRs with increased antigen sensitivity; plus Synthekine, Luminary and more
BioCentury’s roundup of translational news
BioCentury | Jan 20, 2021
Product Development
Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease
Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed
Items per page:
1 - 5 of 5